Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Zynerba Pharmaceuticals, Inc. (ZYNE) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/15/2023 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights",
"FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL"
03/28/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights",
"THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD"
05/12/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights",
"THE STATEMENTS IN THIS PRESENTATION MAY INCLUDE FORWARD"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/10/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights - Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability - - Topline Results from Pivotal Trial in Fragile X Syndrome On Track for 1H2020 - - Phase 2 Topline Results in Autism Spectrum Disorder and 22q11.2 Deletion Syndrome On Track for 1H2020 -"
08/06/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights"
03/11/2019 8-K Quarterly results
11/08/2018 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights"
08/02/2018 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights - Zynerba to host conference call and webcast today at 8:30 am -"
05/08/2018 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights"
03/12/2018 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights"
11/14/2017 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights",
"Zynerba Pharmaceuticals, Inc. Investor Presentation"
08/01/2017 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights Top-line Phase 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017"
05/09/2017 8-K Form 8-K - Current report
03/27/2017 8-K Form 8-K - Current report
11/14/2016 8-K Quarterly results
Docs: "Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights"
08/16/2016 8-K Quarterly results
Docs: "Document 99.1 Press Release, dated August 11, 2016. 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 16, 2016 ZYNERBA PHARMACEUTICALS, INC. By: /s/ Suzanne Hanlon Name: Suzanne Hanlon Title: Secretary, General Counsel and Vice President, Human Resources 4 Exhibit No. Document 99.1 Press Release, dated August 11, 2016.",
"Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes"
05/12/2016 8-K Form 8-K - Current report
11/12/2015 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy